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Paraoxonase-1 (PON1) plays an antioxidant and anti-inﬂammatory role. Aim of the study was to investigate the alteration of
paraoxonase-1 activity in celiac disease (CD), an intestinal disorder characterized by toxic injury exerted by gluten peptides.
Activities of PON1, levels of biochemical markers of lipid peroxidation and total antioxidant capacity were evaluated in serum
obtained from 27 celiac patients (11 at diagnosis, 16 treated with gluten free diet) and 25 healthy subjects. Moreover, the serum
susceptibility of Cu2+-induced lipid peroxidation was investigated in controls and patients. The results showed a lower PON1
activity in serum of both groups of celiac patients with respect to control subjects. PON1 activity in CD was related with markers
of disease severity and was negatively correlated with the levels of lipid hydroperoxide and with the susceptibility of serum to lipid
peroxidation induced in vitro by metal ions. The alteration of PON1 activity and markers of lipid peroxidation realized at lower
extent in patients who were on a gluten-free diet.
1.Introduction
Environmental,genetic,andimmunologicfactorsareinvolv-
ed in the pathogenesis of celiac disease (CD) [1] ,ac h r o n i c
inﬂammatory disease characterised by ﬂattened villi on the
small bowel mucosa. CD is induced by the ingestion of
cereals containing proline-rich and glutamine-rich proteins
(such as wheat, rye, and barley) in genetically susceptible in-
dividuals [2, 3]. From a clinical point of view, CD is cha-
racterised by a clinical heterogeneity that ranges from asym-
ptomatic to severely symptomatic and by increased morbid-
ity and mortality [4]. At present, the only proven treatment
for CD is strict and life-long adherence to a gluten-free diet
(GFD) [1–4].
An increase of markers of oxidative damage of lipids
(thiobarbituric acid-reactive substances and lipid hydroper-
oxides) and proteins (carbonyl groups) and a decrease of
antioxidant enzymes have been demonstrated in plasma, in
circulating cells and in intestinal cells of patients with CD
with respect to controls [5–8]. Higher levels of nitric oxide
(NO) and biochemical markers of oxidative damage of DNA
has been demonstrated in leukocytes and in urine samples of
celiac children [9, 10], suggesting that oxidative stress could
be involved in the pathogenesis of CD.
Paraoxonase-1 (PON1) is an enzyme associated with the
high-density lipoproteins (HDL) that plays both an antioxi-
dant and an anti-inﬂammatory role [11–13]. A decrease in
PON1 has been reported in several human diseases asso-
ciated with inﬂammation and alteration of lipoprotein meta-
bolism [14–17]. Interest in the study of PON1 in celiac dis-
ease is supported by recent studies that have suggested a
possible role of PON1 in inﬂammatory intestinal diseases
[18–20]. Furthermore it has been hypothesised that in
the gastrointestinal tract, PON1 could behave as a local
detoxiﬁer, antioxidant, immunomodulator, and/or quorum-
quenching factor [18].
To further investigate the relationship between oxidative
damage and CD, we studied the levels of lipid peroxides,
total antioxidant capacity, the susceptibility to copper-
induced lipid peroxidation, and the activity of the enzyme
paraoxonase-1 (PON1) in serum of three groups of subjects:
untreated patients with a new diagnosis of celiac disease (CD
patients), CD patients on a gluten-free diet (GFD patients),
and healthy subjects.2 Journal of Lipids
2.MaterialsandMethods
2.1. Subjects Included in the Study. The study included 27
consecutive patients who were referred to the Celiac Disease
Clinic of the Department of Gastroenterology of the Poly-
technic University of Marche, and the study protocol was in
accordance with the ethical standards formulated in Helsinki
Declaration as revised in 2000. Eleven patients (3 males and
8 females, mean age 31.2±11.7 years) had a new diagnosis of
CD (CD patients), whereas 16 (GFD patients; 7 males and 9
females, mean age 35.8±12.1 years) were celiac patients on a
gluten-freediet(meanduration:19.2±5.7months).Twenty-
ﬁve subjects (12 males and 13 females, mean age 39.6 ± 8.1
years) who underwent esophagogastroduodenoscopy for the
presence of dyspeptic syndrome and who did not result to be
aﬀected by CD were used as controls. Subjects with diabetes
and clinical evidence of cardiovascular diseases or receiving
antacids, lipid-lowering drugs, or antioxidant supplements
were excluded from the study to avoid possible interferences
on PON1 activity and plasma lipids.
All subjects included in the study underwent upper gas-
trointestinal endoscopy and at least 4–6 well-oriented duo-
denal specimens were taken for the histological evaluation.
The degree of intestinal mucosal damage was then clas-
siﬁed according to the Marsh classiﬁcation [21]. Thereafter,
each stage was given a score from 0 (normal mucosa) to 5
(total villous atrophy) for statistical analysis.
Serum levels of antitransglutaminase(t-TG) antibodies
were assessed by the laboratory of our institution by using
a commercial FluoroEnzymeImmuno Assay kit (Phadia,
Sweden) and the results were expressed as unit (U)/mL of
serum. A value higher than 10U/mL was considered positive
[22].
In the same day of endoscopy, blood drawn by venous
puncture by fasted subjects was collected into serum-sepa-
rator tubes. After clotting, blood was centrifuged for 15min
at 3500rpm to separate serum that was stored at −80◦C until
examination.
2.2. Serum PON1 Activities. PON1 activity has been evalu-
ated using three diﬀerent substrates [23]: paraoxon for para-
oxonase activity, phenylacetate for arylesterase activity, and
dihydrocoumarin for lactonase activity. All assays were per-
formed in a 96-well plate, in a total reaction volume of
200μL.
2.2.1. Paraoxonase Activity. Serum (10μL, nondiluted sam-
ples) were analyzed. The basal assay mixture included 5mM
Tris-HCl, pH 7.4 containing 0.15MNaCl, 4mMMgCl2,
2mMCaCl 2, and 1.0mmol/L paraoxon. Paraoxon hydrolysis
was spectrophotometrically monitored for 8min (every 15s)
at 412nm. Nonenzymatic hydrolysis of paraoxon was sub-
tracted from the total rate of hydrolysis. One unit of PON1
paraoxonase activity was equivalent to 1nmol of paraoxon
hydrolyzed/min/mL [23].
2.2.2. Arylesterase Activity. The serum samples were diluted
1:10 with 1mmol/L CaCl2 in 50mmol/L Tris HCl, pH
8.0 and then, 5μL was taken for a total reaction volume
of 200μL. After addition of the substrate phenyl acetate
(1.0mmol/L), the hydrolysis was monitored at 270nm for
3min (every 15s). One unit of arylesterase activity was equi-
valent to 1μmol of phenyl acetate hydrolyzed/min/mL [23].
2.2.3. Lactonase Activity toward Dihydrocoumarin (DHC).
The serum samples were diluted 1:10 with 1mmol/LCaCl2
in 50mmol/L Tris HCl, pH 8.0 and 3μL was then taken for
the assay. After addition of the substrate DHC (1.0mmol/L),
the hydrolysis was monitored at 270nm for 10min (every
15s). Nonenzymatic hydrolysis of DHC was subtracted from
the total rate of hydrolysis. One unit of lactonase activity was
equivalent to 1μmol of DHC hydrolyzed/min/mL [23].
2.3. Serum Oxidative Stress Parameters
2.3.1. Serum Basal Oxidative Stress Status. Basal serum oxi-
dative status was determined by the evaluation of the
levels of lipid hydroperoxides using FOX2 assay [15]. Brief-
ly, an aliquot (200μL) of serum was mixed with 1800μL
of FOX2-reagent (250μmol/L ammonium ferrous sulphate,
100μmol/L xylenol-orange, 25mmol/LH2SO4 and 4mmol/
L BHT in 90% methanol (v/v) in 100mL). After incubation
at room temperaturefor 30 minutes, samples were centrifug-
edat4000rpmfor10minutes.Thesupernatantwascarefully
decanted into a cuvette and the absorbance was determined
at 560nm. The levels of lipid hydroperoxides were quantiﬁed
using a stock solution of t-butyl hydroperoxide. The results
were expressed as μmol of lipid hydroperoxides for L of
serum.
2.3.2.Copper-InducedSerumLipidPeroxidation. Serumsam-
ples were diluted 4x with phosphate-buﬀered saline (PBS-
citrate) and were incubated with 50μmol/LCuSO4.S e r u m
lipid peroxidation was monitored by following the kinetic of
conjugated dienes formation at 234nm [24]. The increase
of absorbance was recorded for 6 hours. A KC4 software
was used to calculate the lag times of kinetic of conjugated
dienes formation. The lag time (t-lag, min), deﬁned as the
intercept of the straight lines derived from the lag phase and
the propagation phase, is an index for resistance of serum to
lipid peroxidation [24]. As previously demonstrated longer
lag time indicates a lower susceptibility of serum to lipid
peroxidation [24].
2.4. Serum Total Antioxidant Capacity. Serum total antiox-
idant capacity (TAC) was assessed using the oxygen radical
absorbance capacity (ORAC) assay described by Ou et al.
[25]. The oxygen radical absorbance capacity of serum
employs the oxidative loss of the intrinsic ﬂuorescence of
ﬂuoresceininducedbythefreeradicalinitiator2,2 -azobis(2-
amidinopropane)hydrochloride (AAPH). Trolox was used
as a reference antioxidant for calculating the ORAC values.
Results were expressed as μmol Trolox equivalents/L (μmol
TE/L).
2.5. Statistical Analysis. Data were reported as mean ±
standard deviation (SD). PON1 activities were presented
as medians. For the comparison of normally distributed
variables between groups, Student’s t-test was used. Para-
oxonase-1 activity showed a non-Gaussian distribution;Journal of Lipids 3
Table 1: Clinical characteristics and levels of serum lipids in healthy subjects, celiac patients at diagnosis (CD patients) and celiac patients
treated with a gluten-free diet (GFD patients). Data are given as means ± S.D.
Healthy subjects (n = 25) Celiac patients (n = 27)
CD patients(n = 11) GFD patients (n = 16)
Serum t-TGa (U/mL) 0.4 ±0.2 108.2 ± 35.9∗ 2.3 ±1.9∗#
Damage of intestinal mucosab 04 .4 ±0.6∗ 1.4 ±0.7∗#
Serum triglycerides (mg/dL) 87.140.5± 61.3 ±23.57 1 .2 ±48.2
Serum cholesterol (mg/dL) 186.6 ±43.4 154.1 ±27.6 177.1 ±42.6
Serum HDL-cholesterol (mg/dL) 56.3 ±13.45 1 .1 ±7.95 4 .6 ±8.7
Serum LDL-cholesterol (mg/dL) 113.2 ±23.79 0 .6 ±16.1 108.8 ±26.2
at-TG: antitransglutaminaseantibodies. bDamage of intestinal mucosa was classiﬁed according to Marsh parameters and each stage was given a score from 0
(normal mucosa) to 5 (total villous atrophy).
∗P<0.001 versus healthy subjects; #P<0.05 versus CD patients.
therefore we used a nonparametric test (Wilcoxon rank sum
test). Spearman’s correlation coeﬃcient was used to test the
strength of any association between diﬀerent variables. All
tests were 2-tailed and a P<0.05 level of signiﬁcance was
used to assess statistical signiﬁcance (Microcal Origin 5.0,
OriginLab, Northampton, MA).
3. Results
3.1.ClinicalCharacteristicsoftheStudyPopulation. Asshown
in Table 1, serum levels of anti-t-TG antibodies were within
the normal range in healthy subjects (0.4 ± 0.2U/mL). As
expected,signiﬁcanthigherlevelswereobservedinuntreated
celiac patients (108.2 ± 35.9U/mL). In GFD patients the
levels of anti-t-TG antibodies were signiﬁcantly higher com-
pared with controls but signiﬁcantly lower with respect to
untreated CD patients (Table 1). The degree of intestinal
damage was in the order: controls < GFD patients < CD
patients (Table 1). As summarized in Table 1, the diﬀerences
were statistically signiﬁcant.
3.2. Plasma Lipids in Controls and Celiac Patients. The mean
levels of serum total cholesterol (TC), HDL-cholesterol and
LDL-cholesterol, and triglycerides (TG) were lower in CD
patients with respect to controls, even if the diﬀerences
were not statistically signiﬁcant (Table 1). The levels of plas-
ma lipids in GFD patients were higher with respect to CD
patients, although the diﬀerences were not statistically sig-
niﬁcant (Table 1).
3.3. Serum Paraoxonase-1 Activities in Controls and Celiac
Patients. As summarized in Table 2, the median values of
PON1paraoxonaseactivitywereintheordercontrols>GFD
patients > CD patients. The diﬀerences between both groups
of CD patients compared with controls were statistically
signiﬁcant(Table 2).Themedianvaluesoflactonaseandary-
lesteraseactivitiesofPON1inserumofCDandGFDpatients
were signiﬁcantly lower with respect to controls (Table 2).
PON1 paraoxonase activity was signiﬁcantly correlated with
arylesterase (r = 0.871, n = 52, P<0.0001) and lactonase
(r = 0.875, n = 52, P<0.0001) activities.
3.4. Serum Lipid Peroxidation Markers and Total Antioxidant
Capacity in Controls and Celiac Patients. The levels of lipid
hydroperoxides in control subjects were 2.02 ± 0.76μmol/L.
Higherlevelsoflipidhydroperoxideswereobservedinserum
ofCDandGFDpatientswithrespecttocontrols.Inserumof
GFD patients, the values were signiﬁcantly lower compared
with untreated CD patients (Table 2).
To investigate serum susceptibility to lipid peroxidation
in celiac patients, we evaluated the formation the conjugated
dienes in serum oxidized “in vitro” with copper ions. The
meanvalueofthelagtimeofthekinetic oflipidperoxidation
in serum of controls was 66.4 ± 16.2m i n u t e s( Table 2). The
lag time was signiﬁcantly lower in serum of CD and GFD
patients.InGFDpatientsthelagtimewassigniﬁcantlyhigher
with respect to CD patients (Table 2).
As summarized in Table 2, in GFD patients serum TAC
was lower than controls and signiﬁcantly higher than that of
CD patients.
3.5. Relationship between PON1 Paraoxonase Activity and
Clinical Parameters in Celiac Patients. To study whether the
activity of paraoxonase-1 and markers of oxidative stress
were related to severity of CD, we compared the mean values
of serum levels of anti-t-TG and the degree of mucosal
damage (following Marsh index) in two subgroups of celiac
patients. The ﬁrst group included 14 CD patients having
PON1paraoxonaseactivitybelowthemedianvalueofPON1
observed in all celiac patients (124.6U/mL) (10 untreated
CD and 4 GFD patients). The second group included 13 pa-
tients with PON1 activity above the median value (1 un-
treated CD patient and 12 GFD patients).
As shown in Figure 1, the mean levels of serum anti-
t-TG and the degree of mucosal damage were signiﬁcantly
higher in celiac patients with serum PON1 activity below the
median value with respect to patients with PON1 activity
above the median value. The diﬀerences were statistically
signiﬁcant.
Similar results were observed also for PON1 arylesterase
and lactonase activities (data not shown).
3.6. Correlations between PON1 Paraoxonase Activity and
the Other Markers of Oxidative Stress. The individual values4 Journal of Lipids
Table 2: PON1 activities, markers of lipid oxidative stress (levels of lipid hydroperoxides and lag time of conjugated dienes) and total
antioxidant capacity (TAC) in serum of healthy subjects, celiac patients at diagnosis (CD patients), and celiac patients treated with a gluten-
free diet (GFD patients). Data are given as median (range) for paraoxonase activities and means ± S.D. for other biochemical parameters.
Healthy subjects (n = 25) Celiac patients (n = 27)
CD patients (n = 11) GFD patients (n = 16)
PON1 Activities
Paraoxonase (U/mL) 306 (165.6–608.1) 101.5 (61.2–141.6)∗ 184.9 (75.3–347.8)∗#
Lactonase (U/mL) 68 (32–184) 34 (19.7–68.5)∗ 54.7 (16.5–101.6)∗#
Arylesterase (U/mL) 228 (90–612) 73.2 (41.2–109.7)∗ 105.5 (68.2–148.7)∗#
Lipid hydroperoxides (μmol/L) 2.02 ±0.76 5.31 ± 1.62∗ 4.14 ±1.50∗#
Lag time (min) 66.4 ±16.23 9 .4 ±7.2∗ 46.7 ±12.8∗#
TAC (μM TE) 12048 ±2678 8796 ±976∗ 9977 ±1021∗#
∗P<0.001 versus controls; #P<0.05 versus CD patients.
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Figure 1: Mean levels of antitransglutaminase(t-TG) antibodies
levels (grey square) and degree of damage of intestinal mucosa
classiﬁed according to Marsh parameters (white square) in celiac
patients with PON1 activity above or below the median value
(124.6U/mL). ∗P<0.001 versus celiac patients with PON1 activity
below median value.
of PON1-paraoxonase activity and the levels of serum
hydroperoxides were negatively correlated (r =− 0.735, n =
52, P<0.0001), in agreement with our previous studies
[15]( Figure 2(a)). In the whole group of subjects included
in the study, the enzyme activity was positively correlated
with the lag time of kinetic of lipid peroxidation (r = 0.811,
n = 52, P<0.0001) (Figure 2(b)) and with the values of
total antioxidant capacity (r = 0.74,n = 52, P<0.0001)
(Figure 2(c)). Levels of lipid hydroperoxides were negatively
correlated with total antioxidant capacity (r =− 0.52, n =
52, P<0.0001) and lag-time values (r =− 0.59, n = 52, P<
0.0001).
No signiﬁcant correlation was observed between PON1
activity and HDL cholesterol levels (data not shown).
4. Discussion
The clinical interest in human PON1 has been mainly focus-
ed on atherosclerosis and cardiovascular disease [14, 26],
since PON1 exerts antioxidant and anti-inﬂammatory roles
[14–16]. However, more recently a possible role of PON1 in
the human small intestine in normal and pathological con-
ditions has been suggested [18–20].
Although PON1 paraoxonase activity has been manly
investigated in normal and pathological conditions using
paraoxon as substrate [15–17], we evaluated also PON1 ary-
lesterase and lactonase activities because previous studies
have suggested that serum arylesterase activity could reﬂect
serum enzyme concentration [27] and lactonase activity
could represent a more physiological activity of the enzyme
[28].
Our results demonstrated, for the ﬁrst time, a signiﬁcant
decrease of PON1 activities (paraoxonase, arylesterase, and
lactonase) in serum of celiac patients.
The modiﬁcations of PON1 activities in celiac patients
were related with the severity of the disease and were asso-
ciated with an increase of lipid hydroperoxide levels and with
a higher susceptibility of serum to lipid peroxidation in-
duced “in vitro.” Moreover, a lower serum total antioxidant
capacity (TAC) has been shown in celiac patients. The
values of PON1 activity, markers of lipid peroxidation, and
total antioxidant capacity in GFD patients were signiﬁcantly
diﬀerent compared with healthy subjects and untreated CD
patients.
Our results conﬁrm that CD is associated with oxidative
damage as suggested in previous studies mainly carried out
in CD children [6, 8–10].
Some hypotheses can be made to explain the molecular
mechanisms involved in the lower PON1 activity and the
higher oxidative stress in CD patients (Figure 3).
Previous studies have demonstrated that, in CD patients,
gluten ingestion induces an increased oxidative stress due to
overproduction of free radicals (ROS and RNS) [29–31]. The
higher levels of ROS and the decrease of dietary antioxidant
can trigger lipid peroxidation (LOOH) in intestinal mucosa
and blood lipoproteins.
PON1 is a lipid-dependent enzyme associated with high-
density lipoprotein (HDL) [32]. Previous studies demon-
strated that a decrease of serum PON1 activity could be
related to a lower hepatic synthesis and secretion or to
inhibition exerted by lipid hydroperoxides [27].
No signiﬁcant correlation has been established between
PON1 activity and levels of HDL cholesterol, suggesting thatJournal of Lipids 5
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Figure 2: Correlations between PON1 paraoxonase activity versus the concentrations of serum lipid hydroperoxides (a), versus duration of
the lag-time of Cu2+-oxidized serum (b), versus serum total antioxidant capacity (c) of controls (•) and untreated () or GFD-treated ()
celiac patients.
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Figure 3: Possible molecular mechanisms involved in increased lipid peroxidation and decreased PON1 activity in celiac disease. Gluten
ingestion induces an increased oxidative stress, due to overproduction of free radicals (ROS and RNS) (1). The higher levels of ROS can
trigger lipid peroxidation (LOOH) in intestinal mucosa and blood (2). Oxidative stress could be favored by lower serum antioxidant capacity
resultingfromlower absorptionofdietary antioxidants duetomucosaldamage (3).Alltheaforementioned changes couldexplain thehigher
susceptibility of serum to lipid peroxidation (4) and the compositional alterations of HDL with consequent decrease of PON1 activities (5).
In addition to the inhibition exerted by lipid peroxidation products, the lower PON1 activity could be mediated by inhibition of PON1
synthesis from gastrointestinal cells (6).6 Journal of Lipids
the lower enzyme activity in CD patients is not associated
with alterations of HDL levels.
Although PON1 is mainly synthesised by the liver, it has
been demonstrated that it is expressed also in human ga-
strointestinal tract and Caco-2 cell lines, suggesting that
the intestine, as well as the liver, could represent a source
f o rc i r c u l a t o r yP O N 1[ 33]. Since a decreased expression of
PON1 mRNA has been reported by Rothem L et al. in in-
testinal biopsies of celiac patients [18], we could speculate
that the lower PON1 activity could be related to changes
of the enzyme synthesis from the gastrointestinal tract.
However, contrasting results have been reported on the
synthesis of PON1 in intestinal cells [18, 34–36].
The lower activity of PON1 in CD patients could be also
mediated by inhibition exerted by lipid peroxidation pro-
ducts, since previous studies have shown that PON1 paraox-
onase, arylesterase, and lactonase activities are inhibited by
lipid peroxidation products [37, 38]. This hypothesis is sup-
ported by the signiﬁcant negative correlation found between
PON1 paraoxonase activity and levels of lipid hydroperox-
ides in serum of controls and celiac patients.
The higher susceptibility of serum of celiac patients to
Cu2+-triggered lipid peroxidation, demonstrated in our ex-
perimental conditions, may be related to the lower PON1
activity and/or to the lower serum total antioxidant capacity,
as shown by the signiﬁcant correlations observed between
the lag time of kinetic of lipid peroxidation and PON1 para-
oxonase values and TAC values.
The lower serum total antioxidant capacity in CD pa-
tients could be likely the result of a malabsorption of dietary
antioxidants due to the mucosal damage. In agreement with
this hypothesis other authors have reported lower levels of
antioxidants (retinol, α-tocopherol, and ascorbic acid) in
plasma of CD patients [5, 9]. The mean level of serum total
antioxidant capacity in GFD patients wassigniﬁcantly higher
compared with untreated CD patients, although it did not
reach the values observed in controls; these results suggest
that gluten-free diet is able to only partially improve the
functionality of intestinal mucosa.
Whatever are the causes of the decrease in the activity of
the antioxidant and anti-inﬂammatory enzyme PON1, our
resultsmighthaveaphysiopathologicalrelevance.Infact,the
enzyme PON1 exerts several physiological roles. In the gas-
trointestinal tract PONs proteins and could behave as detox-
iﬁer against food antigens, antioxidant against exogenous
and endogenous lipid peroxides, immunomodulators and/or
inhibitors of bacterial quorum-quenching factor [18, 35].
Moreover, PON1 exerts a protective eﬀect against lipid per-
oxidation of lipoproteins and biological membranes [11–
13]. Oxidative stress is one of the main causes of damage
to cell membranes and lipoproteins. End products of lipid
peroxidation (aldehydes, lipid peroxides) react with biolog-
ical macromolecules such as DNA and proteins and can
cause changes in intestinal cell membrane structure and pro-
perties leading to loss of its integrity [39]. Moreover, lipid
peroxidation products exert biological eﬀects, modulate sig-
naltransductionandithasbeenproposedthattheymayhave
a role in inﬂammatory processes [39].
In conclusion, our results conﬁrm that celiac disease is
associated with oxidative damage and with signiﬁcant de-
crease of PON1 activities. Although a decrease of paraox-
onase-1 activity and an increase of lipid peroxidation prod-
uctsarenotspeciﬁcofceliacdisease[14–17],theycouldexert
a proinﬂammatory and cytotoxic eﬀect and could therefore
contribute to gastrointestinal cell injury in CD.
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